البلد: إسرائيل
اللغة: الإنجليزية
المصدر: Ministry of Health
CARBIDOPA AS MONOHYDRATE; LEVODOPA
ABBVIE BIOPHARMACEUTICALS LTD, ISRAEL
N04BA01
GEL
LEVODOPA 20 MG/ML; CARBIDOPA AS MONOHYDRATE 5 MG/ML
INTESTINAL
Required
ABBVIE DEUTSCHLAND GMBH & CO. KG, GERMANY
LEVODOPA
LEVODOPA
Treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.
2015-04-30
PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS (PREPARATIONS) - 1986 The medicine is dispensed with a doctor’s prescription only DUODOPA Gel for a continuous infusion directly into the digestive system with the help of a designated device Active ingredients: Levodopa 20 mg/ml Carbidopa (as monohydrate) 5 mg/ml Inactive ingredients: See section 6 ‘Further Information’. READ THIS LEAFLET CAREFULLY IN ITS ENTIRETY BEFORE USING THE MEDICINE. This leaflet contains concise information about the medicine. If you have further questions, refer to the doctor or pharmacist. This medicine has been prescribed for the treatment of your ailment. Do not pass it on to others. It may harm them even if it seems to you that their ailment is similar. The medicine is not intended for children and adolescents below the age of 18. In addition to the leaflet, Duodopa has a patient safety information card. This card contains important safety information, which you should know before starting and during the treatment with Duodopa and act accordingly. Read the patient safety information card and the patient leaflet before start using the preparation. Keep the card for further reference if needed. 1. WHAT IS THE MEDICINE INTENDED FOR? Duodopa is intended for the treatment of advanced levodopa- responsive Parkinson’s disease accompanied by severe motor fluctuations and hyper-/dyskinesia when available combinations of medicinal products for the treatment of Parkinson’s have not given satisfactory results. THERAPEUTIC GROUP: anti-Parkinson’s components Levodopa – a dopamine derivative Carbidopa (as monohydrate) – dopa-decarboxylase enzyme inhibitor Duodopa belongs to a group of medicines to treat Parkinson’s disease. It is a gel that goes through a pump and a tube into your gut (small intestine). Duodopa contains two active substances: levodopa and carbidopa (as monohydrate). HOW THE MEDICINE WORKS: ∙ In the body, levodopa is made into “dopamine”. This adds to the dopamine already in your brain اقرأ الوثيقة كاملة
1 DUO API JAN 24 CL PRESCRIBING INFORMATION 1. NAME OF THE MEDICINAL PRODUCT Duodopa _ _ _ _ 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 20 mg levodopa and 5 mg carbidopa monohydrate. 100 ml contain 2000 mg levodopa and 500 mg carbidopa monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Intestinal gel. Off white to slightly yellow gel. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of advanced levodopa- responsive Parkinson’s disease with severe mot or fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Duodopa is a gel for continuous intestinal administration. For long-term administration, the gel should be administered with a portable pump directly into the duodenum or upper jejunum by a permanent tube _via _percutaneous endoscopic gastrostomy with an outer transabdominal tube and an inner intestinal tube. Alternatively, a radiological gastrojejunostomy may be considered if percutaneous endoscopic gastrostomy is not suitable for any reason. Establishment of the transabdominal port and dose adjustments should be carried out in association with a neurological clinic. A temporary nasoduodenal/nasojejunal tube should be considered to determine if the patient responds favourably to this method of treatment before a permanent percutaneous endoscopic gastrostomy with jejunal tube (PEG-J) is placed. In cases where the physician considers this assessment is not necessary, the nasojejunal test phase may be waived and treatment initiated directly with placement of the PEG-J. The dose should be adjusted to an optimal clinical response for the individual patient, which means maximizing the functional ON-time during the day by minimizing the number and duration of OFF episodes (bradykinesia) and minimizing ON- time with disabling dyskinesia. See recommendations under _Dosage. _ PATIENT SAFETY INFORMATION CARD The marketing of Duodopa is sub اقرأ الوثيقة كاملة